Status:
ACTIVE_NOT_RECRUITING
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
Lead Sponsor:
Sun Yat-sen University
Conditions:
Neovascular Glaucoma
Neovascularization
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The clinical trial is aimed to evaluate the anti-neovascular effect of KDR2-2 suspension eyedrop in the treatment of neovascular glaucoma. Fourty subjects would receive either 0.96 or 3.84 mg/per day/...
Detailed Description
Neovascular glaucoma (NVG) has a high blinding rate and poor prognosis. Anti-glaucoma surgery is the main stake of saving visual function and relieving pain, but the proliferation of iris neovasculari...
Eligibility Criteria
Inclusion
- Age 18-75;
- The best-corrected visual acuity (BCVA) of the included eyes was \<0.01 (Snellen chart);
- The BCVA of the contralateral eye of the included subjects was \>0.1;
- Patients with clinically diagnosed neovascular glaucoma; The diagnostic criteria for neovascularization glaucoma were as follows: Intraocular pressure \> 21mmHg measured by Goldmann applanation tonometer; Neovascularization is seen in the iris or anterior chamber angle, with or without corneal edema;
- Compliance with follow up for more than 28 days and written informed consent obtained;
Exclusion
- Intravitreal injection of anti-VEGF drugs within 3 month before enrollment;
- Participation in other clinical trials within 1 month;
- Suffering from other ocular diseases that affect ocular examinations (e.g. keratopathy, uveitis, intraocular infection, etc.);
- Those who plan to receive ocular surgery during the follow-up period;
- Premenopausal women without birth control;
- Having other systemic diseases such as severe liver and kidney function damage, cardiovascular disorders, respiratory disorders, etc.) that may affect the anti-neovascular effect of KDR2-2 or more likely to develop adverse events ;
- Systemic infections under treatment;
- Any study in which the physician believes that the patient's condition will interfere with the clinical trial (e.g., the patient is prone to stress, mood disorders, depression, etc.);
Key Trial Info
Start Date :
April 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04844619
Start Date
April 19 2021
End Date
December 31 2024
Last Update
December 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China, 51000